TrimGen to Debut New Warfarin-Dosing IVD In 'Near Future' as FDA Clearance Nears | GenomeWeb
This article has been updated from a previous version to clarify statements from a TrimGen official about the company's expectations regarding FDA approval for its test. The company said that it has not yet received official notification from the FDA, and that it expects the test to clear in the near future, rather than by the end of the month, as the firm previously stated. 
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.